LatestStudy Shows Puerto Rico's Hospice Industry Contributes $142 Million to Economy
Cannabis

Maryland Veterinarians Now Authorized to Discuss Cannabis Products for Pets

Margaret Jackson
MJBizDaily
AnxietyArthritisChronic Pain
Summary

Maryland's new legislation permits veterinarians to provide guidance on cannabis products for animals, offering pet owners professional medical advice before turning to unregulated dispensaries or online sources. This regulatory shift recognizes the growing interest in cannabinoid therapies for companion animals, particularly for conditions like chronic pain, anxiety, and arthritis. Veterinary consultation ensures proper dosing, product quality, and safety considerations specific to different animal species and individual health profiles. The change addresses a critical gap where pet owners previously sought cannabis solutions without professional veterinary oversight, potentially exposing animals to unsafe products or inappropriate dosing. This development reflects evolving medical and regulatory perspectives on cannabinoid applications in veterinary medicine.

MJ Biz Daily

Originally published on

MJBizDaily

By Margaret Jackson

Read full article(opens in new tab)

Fetched: September 25, 2026 at 10:01 AM

Related News

More news you might be interested in

View all
Study Finds No Link Between THC and Extended Psychiatric Hospital Stays in Depression Cases
Cannabis
DepressionMajor Depressive Disorder

Study Finds No Link Between THC and Extended Psychiatric Hospital Stays in Depression Cases

A new study published in Brain and Behavior analyzed 743 psychiatric hospital admissions for adults with major depression in the United States and found no significant association between THC presence and longer hospital stays or increased 30-day readmission rates. The research challenges assumptions about cannabis use complicating depression treatment outcomes. These findings suggest that THC detection alone may not be a reliable predictor of worse psychiatric hospitalization outcomes in depressed patients. The study provides valuable data for healthcare providers and patients considering cannabis use alongside depression management.

1 hour ago
Revista Cáñamo
Colorado Implements Stricter Testing Standards for Cannabis Concentrates
Cannabis

Colorado Implements Stricter Testing Standards for Cannabis Concentrates

Starting September 28, Colorado will require cannabis testing laboratories to screen for 17 additional residual solvents in chemically-extracted cannabis concentrates. This regulatory enhancement aims to ensure consumer safety by detecting harmful chemical residues that may remain from extraction processes using solvents like butane, propane, or ethanol. The new testing requirements also apply to certain hemp-derived products entering the regulated market. This measure reflects Colorado's commitment to maintaining rigorous quality standards for cannabis products, protecting patients and consumers from potential exposure to toxic solvent residues that could pose respiratory and systemic health risks.

2 hours ago
Revista Cáñamo
Historic Press Freedom Case Rooted in High Times Founder's Pie Protest
Cannabis

Historic Press Freedom Case Rooted in High Times Founder's Pie Protest

A landmark press freedom case that just blocked Trump's media ban traces its origins to Tom Forçade, founder of High Times magazine, who threw a cheese pie at a Commission on Obscenity and Pornography member in the 1970s. When the Secret Service denied Forçade a White House press pass citing the incident, he filed suit alongside Nation correspondent Robert Sherrill in what became the precedent-setting case Sherrill v. Knight. This week, a Trump-appointed federal judge invoked this decades-old ruling to order the White House to restore press credentials for CNN, MS NOW, and Politico, demonstrating how Forçade's act of protest established enduring protections for press access and freedom.

14 hours ago
High Times
Pharmaceutical Cannabis Business Takes Center Stage at Cannaforum 2026
Cannabis

Pharmaceutical Cannabis Business Takes Center Stage at Cannaforum 2026

Cannaforum 2026 revealed that pharmaceutical companies are prioritizing shareholder returns from medical cannabis investments over patient-focused narratives. As a subsection of Farmaforum, the event highlighted the commercial pharmaceutical industry's dominance in shaping the medical cannabis market in Spain. This shift toward profit-driven models raises questions about accessibility and affordability of cannabis-based therapeutics for patients seeking alternative treatments. The emphasis on business dividends suggests that pharmaceutical industry interests may influence how medical cannabis becomes integrated into healthcare systems.

14 hours ago
Soft Secrets (Español)